Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Acasti Pharma Inc ACST

Healthcare
Acasti Pharma Inc. is a Canada-based late-stage biopharma company with drug candidates addressing rare and orphan diseases. The Company is targeting three underserved orphan diseases: GTX-104, an intravenous infusion targeting subarachnoid hemorrhage (SAH), a rare and life-threatening medical emergency, in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull; GTX-102, an oral mucosal spray targeting ataxia-telangiectasia (A-T), a progressive, neurodegenerative genetic disease that primarily impacts children causing severe disability; and GTX-101, a topical spray, targeting postherpetic neuralgia, a persistent and often debilitating neuropathic pain caused by nerve damage from the varicella zoster virus (shingles). The Company’s clinical assets have each been granted Orphan Drug Designation by the FDA, which provides seven years of marketing exclusivity post-launch in the United States, and additional intellectual property protection.


NDAQ:ACST - Post by User

Acasti Pharma Inc > Back in
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(52)
•••
Comment by Francine01on Dec 24, 2019 9:44pm
200 Views
Post# 30489281

RE:RE:RE:RE:RE:Back in

RE:RE:RE:RE:RE:Back inObviously, everyone notice that something weird happen when everyone was waiting for the ph3 T1 results. I have no clue who sold or who is behind the raid attack. I also don’t know if they made their decision based on insider information or not.

i didn’t sold a single share as of today since nov 2017.

SEC and Qubec AMF are big boys, they are free to investigate. If someone from Acasti leaked news or shareholders acted based on material informations not know from the public, they can do their investigation.

I am pretty sure they will have a look on this transaction since millions were made. 

On on my side, I think maganement made a significant mistake not to PR de delay which was a material information risking that some shareholders could buy or sell based on this information.

End of story.

GLTA
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities